menopause glp 1 Hormone Therapy May Boost GLP-1 Drug Benefits Menopause Hormone Therapy Boosts GLP-1

After 40 weeks, tirzepatide significantly outperformed placebo in both glycemic control and weight loss

11th Edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050

The emergence of tri-agonists, combining GLP-1R/GIPR and glucagon (GCG) receptor (GCGR) agonists (GLP-1R/GIPR/GCGR agonist), has also shown promising results by leading to more significant weight loss, a greater percentage of individuals attaining weight loss, further lowering lipid levels, improving T2DM management, and enhancing overall substrate metabolism compared to the use of GLP-1R agonists alone (Lyons & Beaudry 2023)

These criteria usually involve a minimum BMI, often 30 or more, or a BMI of 27 with at least one weight-related health condition

The Functional Medicine Approach to GLP-1 Microdosing As a practitioner of functional medicine, I focus on addressing root causes and optimizing overall health rather than simply treating symptoms